Alterity Therapeutics Ltd
Research Alterity Therapeutics Ltd (ATHE) on Bullrun: market cap USD 56.55M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerATHE
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 56.55M
- Financial periodFY2026
- RevenueAUD 0
- Net income-AUD 23.40M
- Free cash flow-AUD 22.52M
Valuation Snapshot
latest market cap is USD 56.55M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | AUD 0 | -AUD 23.40M | -AUD 22.52M | n/a | -1.33 | AUD 37.32M | AUD 193.47K | AUD 42.72M |
| FY2025 | AUD 0 | -AUD 12.15M | -AUD 11.45M | n/a | -1.14 | AUD 33.16M | AUD 155.46K | AUD 42.40M |
| FY2024 | AUD 0 | -AUD 19.12M | -AUD 12.61M | n/a | -3.12 | AUD 12.64M | AUD 159.05K | AUD 13.80M |
| FY2023 | AUD 0 | -AUD 13.81M | -AUD 20.04M | n/a | -3.42 | AUD 15.77M | AUD 210.38K | AUD 22.81M |
| FY2022 | AUD 0 | -AUD 12.85M | -AUD 12.43M | n/a | -3.18 | AUD 34.81M | AUD 117.49K | AUD 35.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 56.55M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 55.83M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 28.94M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 11.63M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 14.04M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 28.88M | n/a | n/a | n/a |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alterity Therapeutics Ltd's market cap?
Alterity Therapeutics Ltd's market capitalization is USD 56.55M.
What does Alterity Therapeutics Ltd do?
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.